The Chinese Institutes for Medical Research (CIMR) is a new research institution in Beijing dedicated to making ground-breaking discoveries in medical science and translating them into innovative patient care solutions. Established in 2023, CIMR comprises seven research institutes, including the Institute for Cancer Research, the Institute for Cell and Molecular Therapeutics, and the Institute for Immunology. Strategically located on the campus of Capital Medical University (CMU), CIMR leverages unparalleled access to the vast clinical resources of CMU's 23 affiliated hospitals. With a foundation built on three core pillars, world-class research infrastructure, translational agility and collaborative synergy, CIMR is designed to improve human health by driving medical innovation from fundamental research through to clinical application. CIMR fosters a dynamic network connecting medical schools, research institutions, hospitals, venture capital, and industry partners worldwide. As part of its vision to become a premier, world-class research hub, CIMR is actively establishing an international institute. This initiative focuses on recruiting top-tier global scientists and developing collaborative opportunities for joint research programs and international graduate student training.

Beijing Chest Hospital, Capital Medical University (Beijing Institute of Tuberculosis and Thoracic Tumor Research), founded in 1955 and renamed in 2010, is a premier Grade A Tertiary Hospital specializing in thoracic diseases, integrating clinical care, education, research and prevention. It excels in both tuberculosis and thoracic oncology, housing world-class platforms including the WHO Tuberculosis Collaborating Center and a multidisciplinary cancer center. The hospital leads national anti-tuberculosis drug trials with its tuberculosis discipline ranking first in China's STEM for nine consecutive years, while its oncology team has made breakthroughs in lung cancer early screening, precision diagnosis and translational medicine, establishing high-quality clinical databases and achieving significant patent transformations. The hospital trains the next generation of leaders in thoracic medicine through a robust faculty of 48 doctoral and 91 master's supervisors, bridging cutting-edge research with clinical excellence to advance global standards in chest disease care.

Beijing Collaboration Medical Advance Center (CMAC) is a non-profit social organization officially established and inaugurated on March 4, 2024, with the approval of the Administrative Committee of Beijing Economic-Technological Development Area and the Beijing Municipal Bureau of Civil Affairs. Its business scope covers achievement promotion, achievement transformation, technical services, standard formulation, professional consultation, professional training, and professional exhibitions related to the advancement of medical and pharmaceutical innovation. CMAC is committed to conducting research projects in the biomedicine field, providing professional skills training for talents in biomedicine, offering opportunities for industry conferences, exhibitions and exchanges, and building various project platforms in the biomedicine sector. It aims to serve innovative pharmaceutical enterprises, support innovation-driven development, enhance public health and well-being, advance the standardization and professionalization of China’s new drug development and clinical research, comprehensively upgrade the development level of China’s pharmaceutical industry, and actively contribute to safeguarding people’s health.

Medlive Technology Co., Ltd. (2192.HK) is a leading online professional physician platform and healthcare digital marketing service provider in China. Founded in 1996, it has over 7 million registered users, among whom more than 4 million are licensed physicians, accounting for 90% of all licensed physicians across the country. Medlive provides professional medical content, practical tools and diversified products, together with its self-developed AI medical assistant MedSeeker, to support physicians in professional learning, clinical diagnosis and academic research. Medlive also delivers efficient digital academic promotion services for pharmaceutical and medical device companies. Driven by technological innovation, it has built a sound medical communication ecosystem, acting as a solid academic bridge connecting medical practitioners and enterprises, and advancing the high-quality development of China’s healthcare industry.

Nature Reviews Cancer aims to be the premier source of reviews and commentaries for the scientific communities we serve. We strive to publish articles that are authoritative, accessible and enhanced with clearly understandable figures, tables and other display items. We want to provide an unparalleled service to authors, referees and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, Reviews and Perspectives relevant to cancer researchers, with our broad scope ensuring that the articles we publish reach the widest possible audience.

Nature Communications is an open access journal that publishes high-quality research from all areas of the natural sciences. Papers published by the journal represent important advances of significance to specialists within each field.

Nature Cancer aims to provide a unique forum through which the cancer community will learn about the latest, most significant cancer-related advances across the life, physical, applied and social sciences. Areas of interest include fundamental, preclinical research that furthers our understanding of the mechanisms underlying tumour initiation, propagation and progression; work aiming to translate this knowledge to the clinic by focusing on new approaches for the development and delivery of diagnostic and therapeutic modalities; clinical studies informing cancer diagnosis, treatment and prevention; and new ways of understanding the global societal impact of cancer. In addition to publishing original research, Nature Cancer will publish Comments, Reviews, News & Views, Features and Correspondence of high significance across the range of disciplines relating to cancer research.

Nature Genetics is a monthly journal publishing the best research from across the field of genetics, with our broad scope ensuring that work published reaches the widest possible audience. All editorial decisions are made by a team of full-time professional editors.

Nature Progress Oncologyis an open-access journal from Nature Portfolio that publishes high-quality research, reviews and commentary in all areas of cancer research. Research papers published by the journal represent significant advances that bring new insight to a specialized area in oncology research. Nature Progress Oncology complements the other Nature Portfolio journals by providing a high-quality open-access option for key cancer-related findings while applying somewhat less stringent criteria for impact and significance than other Nature-branded journals, including Nature Communications.